Core Insights - Linhai Co., Ltd. (600099.SH) reported a total operating revenue of 801 million yuan for Q3 2025, marking an increase of 39.48 million yuan compared to the same period last year, achieving a year-on-year growth of 5.18% [1] - The net profit attributable to shareholders reached 14.52 million yuan, an increase of 2.29 million yuan year-on-year, reflecting an 18.76% growth and marking five consecutive years of profit increase [1] - The net cash inflow from operating activities was 120 million yuan, up by 27.16 million yuan from the same period last year, representing a 29.34% year-on-year increase and four consecutive years of growth [1] Financial Metrics - The latest debt-to-asset ratio stands at 52.93% [3] - The gross profit margin is reported at 13.26%, a slight increase of 0.02 percentage points from the previous year [3] - Return on equity (ROE) is at 2.71%, up by 0.35 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.07 yuan, an increase of 0.01 yuan compared to the same period last year, achieving an 18.39% year-on-year growth and five consecutive years of increase [3] - The total asset turnover ratio is 0.74 times, while the inventory turnover ratio is 4.82 times [3] Shareholder Structure - The number of shareholders is reported at 12,700, with the top ten shareholders holding a total of 116 million shares, accounting for 53.05% of the total share capital [3] - The largest shareholder is China Foma Machinery Group Co., Ltd., holding 42.1 million shares [3]

Core Insights - Shanghai Pharmaceuticals (601607.SH) reported a total operating revenue of 141.593 billion, ranking first among disclosed peers, with a year-on-year increase of 1.56% [1] - The net profit attributable to shareholders reached 4.459 billion, also ranking first among peers, reflecting a significant year-on-year increase of 51.56% [1] - The net cash flow from operating activities was 989 million, ranking fourth among peers, with a substantial year-on-year increase of 91.98% [1] Financial Metrics - The latest debt-to-asset ratio stands at 62.68%, a decrease of 0.17 percentage points from the same period last year [3] - The gross profit margin is reported at 10.55%, an increase of 0.29 percentage points from the previous quarter [3] - Return on equity (ROE) is at 5.94%, ranking fourth among peers, with a year-on-year increase of 1.73 percentage points [3] - The diluted earnings per share (EPS) is 1.20 yuan, ranking second among peers, with a year-on-year increase of 51.90% [3] - The total asset turnover ratio is 0.62 times, ranking seventh among peers [3] - The inventory turnover ratio is 3.17 times, ranking eleventh among peers [3] Shareholder Structure - The number of shareholders is 85,100, with the top five shareholders holding a total of 2.091 billion shares, accounting for 56.40% of the total share capital [3] - The top five shareholders are: 1. Shanghai Pharmaceuticals (Group) Co., Ltd. - 19.3% 2. Yunnan Baiyao Group Co., Ltd. - 17.9% 3. Shanghai Shun International Investment Co., Ltd. - 8.10% 4. Shanghai Shun (Group) Co., Ltd. - 5.98% 5. Shanghai Tandong Enterprise Consulting Service Co., Ltd. - 5.04% [3]